RT Journal Article
SR Electronic
T1 Cisplatin Plus Ifosfamide with/without Etoposide as Salvage Treatment in Heavily-pre-treated Patients with Metastatic Breast Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5091
OP 5095
VO 35
IS 9
A1 PIET HABBEL
A1 ANNIKA KURRECK
A1 CARSTEN-OLIVER SCHULZ
A1 ANNE CONSTANZE REGIERER
A1 DAVID KAUL
A1 CHRISTIAN WILFRIED SCHOLZ
A1 CHRISTIAN NEUMANN
A1 KURT POSSINGER
A1 JAN EUCKER
YR 2015
UL http://ar.iiarjournals.org/content/35/9/5091.abstract
AB Background: The efficacy of platinum- and ifosfamide-based chemotherapy regimens as salvage treatment in metastatic breast cancer (MBC) has not yet been sufficiently evaluated. Patients and Methods: Patients with MBC treated with cisplatin plus ifosfamide with (PEI) and without (PI) etoposide in our clinic between 04/2005 and 04/2014 were retrospectively analyzed. Results: A total of 20 patients (median four prior chemotherapies) treated with PEI/PI were identified, out of whom 18 were evaluable for objective response. Treatment with PEI/PI resulted in one complete remission, nine partial remissions and two cases of stable disease. The median (range) progression-free survival was 4 (0-18) months and median overall survival from therapy initiation was 8.5 (0-50) months. PEI/PI therapy caused grade 3/4 toxicities (mainly hematological) in 80% of patients. Conclusion: PEI/PI is an adequate salvage treatment for patients with MBC but cannot be generally recommended due to toxicity. However, comparison with platinum monotherapy trials suggests that PEI/PI might be a more effective treatment for patients with triple-negative breast cancer.